NCT04412863 - Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 3, 2020

Primary Completion Date

March 25, 2024

Study Completion Date

March 25, 2024

Conditions

Chronic Hepatitis B

Interventions

DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

DRUG

pegylated interferon-alfa 2a

pegylated interferon-alfa 2a given by subcutaneous injection

Trial Locations (22)

1010

Investigative Site, Auckland

2025

Investigative Site, Auckland

3168

Investigative Site, Fitzroy

4575

Investigative Site, Birtinya

10330

Investigative Site, Bangkok

10400

Investigative Site, Bangkok

10700

Investigative Site, Bangkok

12120

Investigative Site, Khlong Luang

24253

Investigative Site, Chuncheon

25100

Investigative Site, Kuantan

40002

Investigative Site, Khon Kaen

41944

Investigative Site, Daegu

43000

Investigative Site, Kajang

49241

Investigative Site, Busan

50200

Investigative Site, Chiang Mai

50612

Investigative Site, Yangsan

59100

Investigative Site, Kuala Lumpur

68100

Investigative Site, Batu Caves

90110

Investigative Site, Hat Yai

Unknown

Investigative site, Hong Kong

03080

Investigative Site, Seoul

05505

Investigative Site, Seoul